Garen Z. Manvelian
Chief Tech/Sci/R&D Officer at New River Pharmaceuticals, Inc.
Profile
Garen Z.
Manvelian is currently the Chief Medical Officer & Vice President at New River Pharmaceuticals, Inc. He previously worked as the Senior Director-Clinical & Medical Affairs at Pacira Pharmaceuticals, Inc. (California), the Chief Medical Officer & VP-Clinical Development at ImaRx Therapeutics, Inc., and as a Scientist-Clinical Research at Quintiles CNS Therapeutics.
Dr. Manvelian obtained his doctorate degree from Vitebsk State Medical University.
Garen Z. Manvelian active positions
| Companies | Position | Start |
|---|---|---|
New River Pharmaceuticals, Inc.
 New River Pharmaceuticals, Inc. Pharmaceuticals: MajorHealth Technology New River Pharmaceuticals, Inc. develops pharmaceutical products. Its product candidates in clinical development are an amphetamine derivative (NDA filed) and an opioid derivative that they believe will provide alternatives to marketed drugs. The company was founded by Randal J. Kirk in 1996 and is headquartered in Radford, VA. | Chief Tech/Sci/R&D Officer | 2006-10-08 |
Former positions of Garen Z. Manvelian
| Companies | Position | End |
|---|---|---|
Pacira Pharmaceuticals, Inc. (California)
 Pacira Pharmaceuticals, Inc. (California) Medical SpecialtiesHealth Technology Pacira Pharmaceuticals, Inc. develops and manufactures injectable and sustained release therapeutic products. It focuses on clinical and commercial development activities by understanding the needs of the acute care market. The company was founded in March 2007 and is headquartered in San Diego, CA. | Corporate Officer/Principal | - |
| Quintiles CNS Therapeutics | Chief Tech/Sci/R&D Officer | - |
ImaRx Therapeutics, Inc.
 ImaRx Therapeutics, Inc. Pharmaceuticals: MajorHealth Technology ImaRx Therapeutics, Inc. manufactures biopharmaceutical products. The company develops and manufactures therapies for vascular disorders associated with blood clots based on two programs, thrombolytics and sonoLysis. Its therapeutics products are approved by the US Food, Drug Administration and FDA, for the treatment of acute pulmonary embolism or blood clots in the lungs. The company was founded in 1991 and is headquartered in Los Angeles, CA | Chief Tech/Sci/R&D Officer | - |
Training of Garen Z. Manvelian
| Vitebsk State Medical University | Doctorate Degree |
Experiences
Positions held
Connections
1st degree connections
1st degree companies
Male
Female
Members of the board
Executives
Linked companies
| Private companies | 4 |
|---|---|
New River Pharmaceuticals, Inc.
New River Pharmaceuticals, Inc. Pharmaceuticals: MajorHealth Technology New River Pharmaceuticals, Inc. develops pharmaceutical products. Its product candidates in clinical development are an amphetamine derivative (NDA filed) and an opioid derivative that they believe will provide alternatives to marketed drugs. The company was founded by Randal J. Kirk in 1996 and is headquartered in Radford, VA. | Health Technology |
ImaRx Therapeutics, Inc.
ImaRx Therapeutics, Inc. Pharmaceuticals: MajorHealth Technology ImaRx Therapeutics, Inc. manufactures biopharmaceutical products. The company develops and manufactures therapies for vascular disorders associated with blood clots based on two programs, thrombolytics and sonoLysis. Its therapeutics products are approved by the US Food, Drug Administration and FDA, for the treatment of acute pulmonary embolism or blood clots in the lungs. The company was founded in 1991 and is headquartered in Los Angeles, CA | Health Technology |
Pacira Pharmaceuticals, Inc. (California)
Pacira Pharmaceuticals, Inc. (California) Medical SpecialtiesHealth Technology Pacira Pharmaceuticals, Inc. develops and manufactures injectable and sustained release therapeutic products. It focuses on clinical and commercial development activities by understanding the needs of the acute care market. The company was founded in March 2007 and is headquartered in San Diego, CA. | Health Technology |
| Quintiles CNS Therapeutics |
- Stock Market
- Insiders
- Garen Z. Manvelian
